Epirubicin

Chemical formula: C₂₇H₂₉NO₁₁  Molecular mass: 543.519 g/mol  PubChem compound: 41867

Therapeutic indications

Epirubicin is indicated for:

Gastric cancer

Population group: only adults (18 years old or older)

Malignant tumor of stomach

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Papillary transitional cell carcinoma of the bladder, carcinoma-in-situ of the bladder

Population group: only adults (18 years old or older)

When administered intravesically, epirubicin has been shown to be beneficial in the treatment of:

  • Papillary transitional cell carcinoma of the bladder
  • Carcinoma-in-situ of the bladder.
  • Prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Carcinoma of the breast

Population group: only adults (18 years old or older)

Malignant tumor of breast

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Small cell lung cancer

Population group: only adults (18 years old or older)

Small cell carcinoma of lung

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Ovarian cancer

Population group: only adults (18 years old or older)

Malignant tumour of ovary

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Epirubicin is contraindicated in the following cases:

Lactation

Lactation

Persistent myelosuppression

Myelosuppression

Severe hepatic impairment

Hepatic failure stage IV

Severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias, unstable angina pectoris, myocardiopathy

at least one of
Heart failure New York Heart Assosiation Class IΙΙ
Heart failure New York Heart Assosiation Class IV
Recent myocardial infarction
Myocardial infarction
Arrhythmia
Preinfarction syndrome
Cardiomyopathy

Acute systemic infections

Systemic infection

Invasive tumours penetrating the bladder

Carcinoma of urinary bladder, invasive

Hematuria

Hematuria

Cystitis

Cystitis

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: EPIRUBICIN HYDROCHLORIDE Solution for injection or infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈